Key result
Supervised exercise therapy improves maximum walking distance by ~89 meters from baseline in PAD patients.
Why the study?
This study aimed to analyze the effect of a novel supervised exercise therapy program combining intermittent treadmill walking and circuit-based moderate-intensity functional training on walking performance and health-related quality of life in peripheral arterial disease patients.
Does a 12-week supervised combined exercise training program improve walking performance and quality of life in patients with peripheral arterial disease?
Does a 12-week supervised combined exercise training program improve walking performance and quality of life in patients with peripheral arterial disease?
p-value: p=< 0.05
A 12-week supervised combined exercise program improves walking performance and quality of life in PAD patients, but these benefits are lost upon cessation of the exercise.
May improve walking distance in PAD; hypothesis-generating pending RCTs to confirm durability and causality.
OBJECTIVE: This study aimed to analyze the effect of a novel supervised exercise therapy program based on intermittent treadmill walking and circuit-based moderate-intensity functional training on walking performance and health-related quality of life in peripheral arterial disease patients. DESIGN: All participants underwent a 12-wk supervised exercise therapy that involved 15-30 mins of treadmill walking followed by a 15-min moderate-intensity functional training continued by 12-wk follow-up. Maximum walking distance, pain-free walking distance, gait speed, and estimated peak oxygen uptake (peak VO 2 ) were calculated through the 6-min walk test and health-related quality of life through the Short-Form 36 and the Vascular Quality of Life Questionnaire 6. RESULTS: There were statistically significant differences ( P < 0.05) between baseline and postintervention for walking performance outcomes (maximum walking distance [mean difference: 88.53 m], pain-free walking distance [mean difference: 62.89 m], gait speed [mean difference: 0.24 m·sec -1 ], and peak VO2 [mean difference: 2.04 ml·kg -1 ·min -1 ]) and for health-related quality of life (physical functioning in Short-Form 36 [mean difference: 6.93 points] and Vascular Quality of Life Questionnaire 6 [mean difference: 1.46 points]), while no differences were found between baseline and 12-wk follow-up. CONCLUSIONS: Results seem to show that 12-wk novel supervised exercise therapy based on intermittent walking and moderate-intensity functional training induced significant clinical improvements in key functional variables of peripheral arterial disease while cessation of exercise leads to significant negative clinical changes in subsequent weeks of follow-up.
No takes yet. Share an insight, caveat, or question.
Peñín‐Grandes et al. (2025) studied peripheral arterial disease. supervised exercise therapy vs. baseline was evaluated on walking performance and health-related quality of life (p=< 0.05). A 12-week supervised exercise therapy program significantly improved maximum walking distance (mean difference 88.53 m, P<0.05) in peripheral arterial disease patients compared to baseline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: